SR-3677 is a potent and selective ROCK-II inhibitor with an IC50 of ~3 nM in enzyme and cell based assays, and its IC50 for ROCK-I is 56 ± 12 nM.

Verosudil, also known as AR-12286, is a potent and selective Rho kinase inhibitor. AR-12286 was well tolerated and provided statistically significant reduction in IOP (intraocular pressure) in patients with XFS (exfoliation syndrome) and OHT (ocular hypertension) or XFG (exfoliative glaucoma). This drug may represent an additional therapeutic paradigm for the treatment of XFG.

RKI-1313 is a negative control for RKI-1447 (GLXC-05200) which is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.

GSK269962A is a potent ROCK inhibitor (IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively), and displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases.

CMPD101 is a selective GRK2/3 inhibitor with IC50 values of 32 and 54 nM for GRK3 and GRK2, respectively.

SLx-2119 is a small molecule and selective inhibitor of ROCK2 with IC50 of 105 nM, which is over 200 fold selecivity over ROCK1 (IC50 =24 μM).

GSK269962 HCl is a selective ROCK (Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.

H-1152 2HCl, an isoquinolinesulfonamide derivative, is a more specific, stronger and membrane-permeable inhibitor of Rho-kinase with a Ki value of 1.6 nM, but poor inhibitor of other serine/threonine kinases.

Chroman 1 is a highly potent and selective ROCK II inhibitor.